- Coordinator
- Universite Libre De Bruxelles, Belgium
- Runs
- 1 January 2023 to 31 December 2027
- Status
- Running
- EU funding
- €12.0m
- Total cost
- €12.0m
- Partners
- 15 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101096312
What the project is doing
In the project's own words, from its summary on CORDIS.
Alcohol-related hepatocellular carcinoma (ALD-HCC) is, in Europe, the leading cause of liver cancer (2nd most common cause of cancer-related death worldwide, affecting both men and women). ALD-HCC has a median 5-year survival rate of 15%. Yet, the prognosis is driven by the tumour stage, with curative options providing a 5-year survival exceeding 70% for early-stage HCC (<20% of cases). Therefore, interventions aiming to improve prevention and early detection are key.
ALD-HCC results from the interplay between environmental determinants and genetic variations. A comprehensive characterisation of environmental factors (e.g. diet, lifestyle) linked to ALD-HCC is still lacking. We recently performed the 1st genome-wide association study of ALD-HCC and identified predisposing genetic variations. However, their role on alcohol-related liver carcinogenesis needs clarification and the genetic architecture of ALD-HCC remains mostly unknown.
GENIAL brings together partners with unique expertise in clinical hepatology, single-cell and spatial multi-omics, artificial intelligence (AI) and communication and dissemination capacities. Our aim is to 1) portray genetic and environmental determinants promoting ALD-HCC; 2) evaluate how they interact at cellular level in human samples and preclinical models to get novel insights into liver carcinogenesis, and identify chemopreventive targets; and 3) assess how these determinants modulate the ALD-HCC risk in prospective cohorts of patients included in HCC surveillance programs.
Environmental factors will be comprehensively characterised in an ongoing clinical trial designed to evaluate alternative methods for early-stage HCC detection. Finally, AI models, reaching the minimal viable product stage by the end of GENIAL, will be used to integrate genetic and non-genetic information (including digital imaging) to develop novel cost-effective strategies towards prevention and early-stage detection of ALD-HCC in at-risk individuals.
This action is part of the Cancer Mission cluster of projects on ‘‘Understanding’.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite Libre De Bruxelles | Bruxelles | Belgium | Coordinator |
| European Liver Patients Association | Bruxelles / Brussel | Belgium | Participant |
| Vib Vzw | Zwijnaarde - Gent | Belgium | Participant |
| European Association for the Studyof the Liver | Geneve | Switzerland | Associatedpartner |
| Technische Universitaet Dresden | Dresden | Germany | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Epsa Innovation France | Issy-Les-Moulineaux | France | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Universite Paris 13 | Villetaneuse | France | Participant |
| Universite Paris Cite | Paris | France | Participant |
| Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico | Milano | Italy | Participant |
| Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico | Milano | Italy | Third party |
| Universita Degli Studi Di Milano | Milano | Italy | Participant |
| Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud | Lisboa | Portugal | Participant |
| StratiPath AB | Solna | Sweden | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI